A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer

S. Cascinu, F. Graziano, S. Barni, R. Labianca, G. Comella, R. Casaretti, L. Frontini, V. Catalano, A. M. Baldelli, G. Catalano

Research output: Contribution to journalArticle

Abstract

In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim. Chemotherapy-naive patients with relapsed or metastatic gastric cancer received 8 weekly administrations of chemotherapy with cisplatin 40 mg/m2, fluorouracil 500 mg/m2, epidoxorubicin 35 mg/m2, 6S-steroisomer of leucovorin 250 mg/m2 and glutathione 1.5 g/m2. On the other days filgrastim 5 μg kg-1 was administered by subcutanous injection. Subsequently, patients with partial response or stable disease received 3 cycles of docetaxel 100 mg/m2 every 3 weeks. 40 patients have been enrolled and they are evaluable for response and toxicity. After the PELF regimen, 3 patients achieved complete response, 13 patients showed partial response, 21 patients had stable disease and 3 patients progressed (40% response rate; 95% CI 25% to 55%). After docetaxel, 9 out 34 patients improved the outcome (26.5%); 7 patients with stable disease achieved partial response and 2 patients with partial response achieved complete response. The overall response rate in the 40 patients was 57.5% (95% CI, 42.5% to 72.5%). The PELF regimen did not cause any grade IV toxicity, the most frequent grade III acute side-effects were thrombocytopenia and vomiting which occurred in the 10% of 320 PELF cycles. Docetaxel caused grade III-IV neutropenia and thrombocytopenia in the 10% and the 19% of cycles respectively. Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy. The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)470-474
Number of pages5
JournalBritish Journal of Cancer
Volume84
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

docetaxel
Stomach Neoplasms
Gastrointestinal Tract
Drug Therapy
Neoplasms
Fluorouracil
Thrombocytopenia
Cisplatin
Levoleucovorin

Keywords

  • Docetaxel
  • Gastric cancer
  • Sequential chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. / Cascinu, S.; Graziano, F.; Barni, S.; Labianca, R.; Comella, G.; Casaretti, R.; Frontini, L.; Catalano, V.; Baldelli, A. M.; Catalano, G.

In: British Journal of Cancer, Vol. 84, No. 4, 2001, p. 470-474.

Research output: Contribution to journalArticle

Cascinu, S. ; Graziano, F. ; Barni, S. ; Labianca, R. ; Comella, G. ; Casaretti, R. ; Frontini, L. ; Catalano, V. ; Baldelli, A. M. ; Catalano, G. / A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. In: British Journal of Cancer. 2001 ; Vol. 84, No. 4. pp. 470-474.
@article{a16120d5178d4b96b6bda953a0108dda,
title = "A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer",
abstract = "In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim. Chemotherapy-naive patients with relapsed or metastatic gastric cancer received 8 weekly administrations of chemotherapy with cisplatin 40 mg/m2, fluorouracil 500 mg/m2, epidoxorubicin 35 mg/m2, 6S-steroisomer of leucovorin 250 mg/m2 and glutathione 1.5 g/m2. On the other days filgrastim 5 μg kg-1 was administered by subcutanous injection. Subsequently, patients with partial response or stable disease received 3 cycles of docetaxel 100 mg/m2 every 3 weeks. 40 patients have been enrolled and they are evaluable for response and toxicity. After the PELF regimen, 3 patients achieved complete response, 13 patients showed partial response, 21 patients had stable disease and 3 patients progressed (40{\%} response rate; 95{\%} CI 25{\%} to 55{\%}). After docetaxel, 9 out 34 patients improved the outcome (26.5{\%}); 7 patients with stable disease achieved partial response and 2 patients with partial response achieved complete response. The overall response rate in the 40 patients was 57.5{\%} (95{\%} CI, 42.5{\%} to 72.5{\%}). The PELF regimen did not cause any grade IV toxicity, the most frequent grade III acute side-effects were thrombocytopenia and vomiting which occurred in the 10{\%} of 320 PELF cycles. Docetaxel caused grade III-IV neutropenia and thrombocytopenia in the 10{\%} and the 19{\%} of cycles respectively. Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy. The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy.",
keywords = "Docetaxel, Gastric cancer, Sequential chemotherapy",
author = "S. Cascinu and F. Graziano and S. Barni and R. Labianca and G. Comella and R. Casaretti and L. Frontini and V. Catalano and Baldelli, {A. M.} and G. Catalano",
year = "2001",
doi = "10.1054/bjoc.2000.1631",
language = "English",
volume = "84",
pages = "470--474",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer

AU - Cascinu, S.

AU - Graziano, F.

AU - Barni, S.

AU - Labianca, R.

AU - Comella, G.

AU - Casaretti, R.

AU - Frontini, L.

AU - Catalano, V.

AU - Baldelli, A. M.

AU - Catalano, G.

PY - 2001

Y1 - 2001

N2 - In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim. Chemotherapy-naive patients with relapsed or metastatic gastric cancer received 8 weekly administrations of chemotherapy with cisplatin 40 mg/m2, fluorouracil 500 mg/m2, epidoxorubicin 35 mg/m2, 6S-steroisomer of leucovorin 250 mg/m2 and glutathione 1.5 g/m2. On the other days filgrastim 5 μg kg-1 was administered by subcutanous injection. Subsequently, patients with partial response or stable disease received 3 cycles of docetaxel 100 mg/m2 every 3 weeks. 40 patients have been enrolled and they are evaluable for response and toxicity. After the PELF regimen, 3 patients achieved complete response, 13 patients showed partial response, 21 patients had stable disease and 3 patients progressed (40% response rate; 95% CI 25% to 55%). After docetaxel, 9 out 34 patients improved the outcome (26.5%); 7 patients with stable disease achieved partial response and 2 patients with partial response achieved complete response. The overall response rate in the 40 patients was 57.5% (95% CI, 42.5% to 72.5%). The PELF regimen did not cause any grade IV toxicity, the most frequent grade III acute side-effects were thrombocytopenia and vomiting which occurred in the 10% of 320 PELF cycles. Docetaxel caused grade III-IV neutropenia and thrombocytopenia in the 10% and the 19% of cycles respectively. Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy. The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy.

AB - In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim. Chemotherapy-naive patients with relapsed or metastatic gastric cancer received 8 weekly administrations of chemotherapy with cisplatin 40 mg/m2, fluorouracil 500 mg/m2, epidoxorubicin 35 mg/m2, 6S-steroisomer of leucovorin 250 mg/m2 and glutathione 1.5 g/m2. On the other days filgrastim 5 μg kg-1 was administered by subcutanous injection. Subsequently, patients with partial response or stable disease received 3 cycles of docetaxel 100 mg/m2 every 3 weeks. 40 patients have been enrolled and they are evaluable for response and toxicity. After the PELF regimen, 3 patients achieved complete response, 13 patients showed partial response, 21 patients had stable disease and 3 patients progressed (40% response rate; 95% CI 25% to 55%). After docetaxel, 9 out 34 patients improved the outcome (26.5%); 7 patients with stable disease achieved partial response and 2 patients with partial response achieved complete response. The overall response rate in the 40 patients was 57.5% (95% CI, 42.5% to 72.5%). The PELF regimen did not cause any grade IV toxicity, the most frequent grade III acute side-effects were thrombocytopenia and vomiting which occurred in the 10% of 320 PELF cycles. Docetaxel caused grade III-IV neutropenia and thrombocytopenia in the 10% and the 19% of cycles respectively. Fatigue was a frequent side-effect during both PELF and docetaxel chemotherapy. The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy.

KW - Docetaxel

KW - Gastric cancer

KW - Sequential chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=17744389781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744389781&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2000.1631

DO - 10.1054/bjoc.2000.1631

M3 - Article

C2 - 11207039

AN - SCOPUS:17744389781

VL - 84

SP - 470

EP - 474

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -